🇺🇸 SECOCULAR THERAPEUTIX, INCDoubao · 实盘不做把握 8/10不做原因:标的无直接敞口
北京时间·🕒 发布 04:15:32·⟳ 抓取 04:15:55 +23s·⚡ 决策 10-17 04:16:42 +47s·10.9 天前
Ocular Therapeutix 首席战略官 Sanjay Nayak 离职出任一家私营公司 CEO
Item 5.02 仅披露首席战略官（非 CEO/董事长/核心研发负责人）主动辞职去另一家私营公司当 CEO，属于正常人才流动；公告无指引、财务、管线、控制权或补偿条款等任何定价信息，方向性 edge 不成立。
📄 原文OCULAR THERAPEUTIX, INC↗ 原文
----- tm2627709d1_8k.htm ----- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT…
不做 Ocular Therapeutix, Inc.（OCUL.US）
Item 5.02 常规人事披露：首席战略官主动辞职赴任私营公司 CEO，非 CEO/CFO/核心研发负责人离职、无指引或管线变化、无控制权事项，无方向性 edge，盘后亦无可成交窗口，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Ocular Therapeutix 8-K 只披露首席战略官 Sanjay Nayak 主动离职、出任一家私营公司 CEO，无继任震荡、无业绩或管线信息，属常规人事变更，不构成多空催化，回避。
🔎 新鲜度:最早出现 2026-10-16 · 扩散 low · price-in 风险 low ↗
主要风险
- 若 Nayak 实际深度主导核心管线（如 OTX-TKI/DEXTENZA 商业化战略），其离开可能影响中长期执行，但公告未提供此类证据，属存量风险而非本事件催化
先例如何影响了这次决策
对本次决策的影响:确认此类行政性 Item 5.02 披露不进入交易，不改变结论
方向:无可对照先例；单一非 CEO 高管离职在 biotech 板块普遍不产生方向性定价，无需据此构建事件研究面板
涨幅量级:不足以支撑任何幅度校准
形态:无
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 9 ms
{"result": "search_processed_events:agent query=`ocul 8-k item 5.02 cso resigns october 2026 | ocular therapeutix sanjay nayak chief strategy officer resignation | sanjay nayak 离职 ocular therapeutix 首席战略官`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消
原文全文
展开原文 · 2,673 字
----- tm2627709d1_8k.htm -----
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 14, 2026
OCULAR
THERAPEUTIX, INC.
(Exact Name of Registrant as Specified in its
Charter)
Delaware
001-36554
20-5560161
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
14
Crosby Drive, 3rd Floor
Bedford
,
MA
01730
(Address of Principal Executive Offices) (Zip
Code)
Registrant’s telephone number, including area
code:
(
781
)
357-4000
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of
each exchange on which
registered
Common
Stock, $0.0001 par value per share
OCUL
The
Nasdaq Global Market
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 5.02
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 14, 2026, Sanjay Nayak, M.B.B.S., Ph.D.,
Chief Strategy Officer of Ocular Therapeutix, Inc. (the “Company”), notified the Company of his resignation from the Company,
effective October 16, 2026, to become the Chief Executive Officer of a privately-held company.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
OCULAR THERAPEUTIX, INC.
Date: October 16, 2026
By:
/s/ Jason S. Robins
Jason S. Robins
Chief Financial Officer
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 14, 2026
OCULAR
THERAPEUTIX, INC.
(Exact Name of Registrant as Specified in its
Charter)
Delaware
001-36554
20-5560161
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
14
Crosby Drive, 3rd Floor
Bedford
,
MA
01730
(Address of Principal Executive Offices) (Zip
Code)
Registrant’s telephone number, including area
code:
(
781
)
357-4000
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of
each exchange on which
registered
Common
Stock, $0.0001 par value per share
OCUL
The
Nasdaq Global Market
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 5.02
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 14, 2026, Sanjay Nayak, M.B.B.S., Ph.D.,
Chief Strategy Officer of Ocular Therapeutix, Inc. (the “Company”), notified the Company of his resignation from the Company,
effective October 16, 2026, to become the Chief Executive Officer of a privately-held company.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
OCULAR THERAPEUTIX, INC.
Date: October 16, 2026
By:
/s/ Jason S. Robins
Jason S. Robins
Chief Financial Officer
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
0d0eac7233· 2026-10-17 04:16 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前